Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.33
SWTUY's Cash to Debt is ranked higher than
54% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. SWTUY: 0.33 )
SWTUY' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 0.33

Equity to Asset 0.71
SWTUY's Equity to Asset is ranked higher than
78% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. SWTUY: 0.71 )
SWTUY' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.77
Current: 0.71

0.48
0.77
Interest Coverage No Debt
SWTUY's Interest Coverage is ranked higher than
72% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. SWTUY: No Debt )
SWTUY' s 10-Year Interest Coverage Range
Min: 1.1   Max: 9999.99
Current: No Debt

1.1
9999.99
F-Score: 5
Z-Score: 7.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11.83
SWTUY's Operating margin (%) is ranked higher than
67% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. SWTUY: -11.83 )
SWTUY' s 10-Year Operating margin (%) Range
Min: -16.67   Max: 29.1
Current: -11.83

-16.67
29.1
Net-margin (%) -10.50
SWTUY's Net-margin (%) is ranked higher than
67% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. SWTUY: -10.50 )
SWTUY' s 10-Year Net-margin (%) Range
Min: -29.4   Max: 22.31
Current: -10.5

-29.4
22.31
ROE (%) -5.74
SWTUY's ROE (%) is ranked higher than
69% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. SWTUY: -5.74 )
SWTUY' s 10-Year ROE (%) Range
Min: -24.5   Max: 19.35
Current: -5.74

-24.5
19.35
ROA (%) -4.14
SWTUY's ROA (%) is ranked higher than
70% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. SWTUY: -4.14 )
SWTUY' s 10-Year ROA (%) Range
Min: -14.82   Max: 16.94
Current: -4.14

-14.82
16.94
ROC (Joel Greenblatt) (%) -23.52
SWTUY's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. SWTUY: -23.52 )
SWTUY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -32.93   Max: 20.36
Current: -23.52

-32.93
20.36
Revenue Growth (3Y)(%) -4.90
SWTUY's Revenue Growth (3Y)(%) is ranked higher than
66% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. SWTUY: -4.90 )
SWTUY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -34.2   Max: 1.8
Current: -4.9

-34.2
1.8
EBITDA Growth (3Y)(%) 71.00
SWTUY's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. SWTUY: 71.00 )
SWTUY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.7   Max: 71
Current: 71

-43.7
71
EPS Growth (3Y)(%) -12.90
SWTUY's EPS Growth (3Y)(%) is ranked higher than
68% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. SWTUY: -12.90 )
SWTUY' s 10-Year EPS Growth (3Y)(%) Range
Min: -50.7   Max: -12.9
Current: -12.9

-50.7
-12.9
» SWTUY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SWTUY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.62
SWTUY's P/B is ranked higher than
71% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.49 vs. SWTUY: 4.62 )
SWTUY' s 10-Year P/B Range
Min: 0.66   Max: 5.58
Current: 4.62

0.66
5.58
P/S 8.31
SWTUY's P/S is ranked higher than
62% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.14 vs. SWTUY: 8.31 )
SWTUY' s 10-Year P/S Range
Min: 1.07   Max: 10.56
Current: 8.31

1.07
10.56
PFCF 133.14
SWTUY's PFCF is ranked higher than
80% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SWTUY: 133.14 )
SWTUY' s 10-Year PFCF Range
Min: 12.61   Max: 723.08
Current: 133.14

12.61
723.08
EV-to-EBIT -74.57
SWTUY's EV-to-EBIT is ranked higher than
56% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SWTUY: -74.57 )
SWTUY' s 10-Year EV-to-EBIT Range
Min: -5346.2   Max: 642.9
Current: -74.57

-5346.2
642.9
Current Ratio 2.68
SWTUY's Current Ratio is ranked higher than
72% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. SWTUY: 2.68 )
SWTUY' s 10-Year Current Ratio Range
Min: 1.67   Max: 3.23
Current: 2.68

1.67
3.23
Quick Ratio 1.69
SWTUY's Quick Ratio is ranked higher than
64% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. SWTUY: 1.69 )
SWTUY' s 10-Year Quick Ratio Range
Min: 0.66   Max: 1.85
Current: 1.69

0.66
1.85

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 69.52
SWTUY's Price/Tangible Book is ranked higher than
61% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.53 vs. SWTUY: 69.52 )
SWTUY' s 10-Year Price/Tangible Book Range
Min: 1.17   Max: 2090
Current: 69.52

1.17
2090
Price/DCF (Projected) 6.50
SWTUY's Price/DCF (Projected) is ranked higher than
80% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. SWTUY: 6.50 )
SWTUY' s 10-Year Price/DCF (Projected) Range
Min: 3.12   Max: 8
Current: 6.5

3.12
8
Price/Median PS Value 2.29
SWTUY's Price/Median PS Value is ranked higher than
62% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. SWTUY: 2.29 )
SWTUY' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.76
Current: 2.29

0.31
2.76
Earnings Yield (Greenblatt) -1.30
SWTUY's Earnings Yield (Greenblatt) is ranked higher than
70% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. SWTUY: -1.30 )
SWTUY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 1.7
Current: -1.3

0.2
1.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:0MTD.UK, SOBI.Sweden, B6E.Germany,
Swedish Orphan Biovitrum AB is a Sweden-based pharmaceutical company that markets specialist pharmaceuticals worldwide. Its research and development is focused on the development and production of biotechnology therapeutics within the areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care, and malabsorption. The company produces specialist pharmaceuticals that are intended to target small patient groups and are prescribed by medical specialists, as well as biopharmaceuticals, recombinant proteins produced using biotechnological processes similar to the body's own substances. The company develops its products either internally, or through partnerships with other pharmaceutical companies. Biovitrium promotes its proprietary products and prescription specialist products throughout Europe, North America, Australia, and New Zealand, in collaboration with Wyeth, Amgen, and other pharmaceutical and biotechnology comapanies. The company's pipeline includes the following products: Kepivance, a recombinant protein drug used to prevent inflammation and ulcers of the oral mucosa in patients suffering from hematologic cancer; Kiobrina, a recombinant human lipid-digesting enzyme (BSSL) for the purpose of improving fat absorption and increasing growth in premature infants; Exinalda, a biotechnologically produced recombinant human enzyme to improve treatment for patients suffering from fat malabsorption due to pancreatic insufficiency in diseases such as cystic fibrosis (CF); Factor IX Fc, a recombinant protein drug developed in combination with Biogen Idec for the treatment of hemophilia B, to name a few.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK